Pharmaron Schedules Board Meeting for 27 October to Approve Q3 2026 Results

Bulletin Express

Yesterday

The board of directors of Pharmaron Beijing Co., Ltd. has set 27 October 2026 (Tuesday) as the date to convene and consider approval of the company’s third-quarter results for the nine months ended 30 September 2026. The session will also address the formal release of these financial figures to the market.

The meeting will be chaired by Dr. Lou Boliang, who currently leads a board comprising three executive directors (Dr. Lou Boliang, Mr. Lou Xiaoqiang, Ms. Zheng Bei), one employee representative director (Mr. Li Shing Chung Gilbert), one non-executive director (Ms. Wan Xuan), and three independent non-executive directors (Ms. Li Lihua, Prof. Tsang King Fung, Ms. Shen Rong).

The forthcoming financial disclosure will provide an updated view of Pharmaron’s performance for the first three quarters of 2026 and is expected to be published shortly after the board’s deliberation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigermarketd.com/news/1120071884"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120071884\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120071884?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-13 16:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120071884","market":"hk","top_or_hot":-1,"title":"Pharmaron Schedules Board Meeting for 27 October to Approve Q3 2026 Results","media":"Bulletin Express","content":"<p>The board of directors of Pharmaron Beijing Co., Ltd. has set 27 October 2026 (Tuesday) as the date to convene and consider approval of the company’s third-quarter results for the nine months ended 30 September 2026. The session will also address the formal release of these financial figures to the market.</p>\n<p>The meeting will be chaired by Dr. Lou Boliang, who currently leads a board comprising three executive directors (Dr. Lou Boliang, Mr. Lou Xiaoqiang, Ms. Zheng Bei), one employee representative director (Mr. Li Shing Chung Gilbert), one non-executive director (Ms. Wan Xuan), and three independent non-executive directors (Ms. Li Lihua, Prof. Tsang King Fung, Ms. Shen Rong).</p>\n<p>The forthcoming financial disclosure will provide an updated view of Pharmaron’s performance for the first three quarters of 2026 and is expected to be published shortly after the board’s deliberation.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaron Schedules Board Meeting for 27 October to Approve Q3 2026 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaron Schedules Board Meeting for 27 October to Approve Q3 2026 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-10-13 16:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The board of directors of Pharmaron Beijing Co., Ltd. has set 27 October 2026 (Tuesday) as the date to convene and consider approval of the company’s third-quarter results for the nine months ended 30 September 2026. The session will also address the formal release of these financial figures to the market.</p>\n<p>The meeting will be chaired by Dr. Lou Boliang, who currently leads a board comprising three executive directors (Dr. Lou Boliang, Mr. Lou Xiaoqiang, Ms. Zheng Bei), one employee representative director (Mr. Li Shing Chung Gilbert), one non-executive director (Ms. Wan Xuan), and three independent non-executive directors (Ms. Li Lihua, Prof. Tsang King Fung, Ms. Shen Rong).</p>\n<p>The forthcoming financial disclosure will provide an updated view of Pharmaron’s performance for the first three quarters of 2026 and is expected to be published shortly after the board’s deliberation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1120071884","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120071884","pubTimestamp":1791880914,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"The board of directors of Pharmaron Beijing Co., Ltd. has set 27 October 2026 (Tuesday) as the date to convene and consider approval of the company’s third-quarter results for the nine months ended...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"康龙化成定于 10 月 27 日召开董事会会议批准 2026 年第三季度业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"The board of directors of Pharmaron Beijing Co., Ltd. has set 27 October 2026 (Tuesday) as the date to convene and consider approval of the company’s third-quarter results for the nine months ended 30 September 2026. The session will also address the formal release of these financial figures to the market.\nThe meeting will be chaired by Dr. Lou Boliang, who currently leads a board comprising three executive directors (Dr. Lou Boliang, Mr. Lou Xiaoqiang, Ms. Zheng Bei), one employee representative director (Mr. Li Shing Chung Gilbert), one non-executive director (Ms. Wan Xuan), and three independent non-executive directors (Ms. Li Lihua, Prof. Tsang King Fung, Ms. Shen Rong).\nThe forthcoming financial disclosure will provide an updated view of Pharmaron’s performance for the first three quarters of 2026 and is expected to be published shortly after the board’s deliberation.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}